Hyperprogression in advanced melanoma is not restricted to immunotherapy.
Fiche publication
Date publication
août 2023
Journal
European journal of cancer (Oxford, England : 1990)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr DALAC Sophie
Tous les auteurs :
Fournier M, Mortier L, Dereure O, Dalac S, Oriano B, Dalle S, Lebbé C
Lien Pubmed
Résumé
The definition of hyperprogressive disease (HPD) is controversial in the literature and has not been widely described in melanoma. The aim of this study was to determine whether the concept of HPD applies to patients treated for advanced melanoma, using a definition with a simple, reproducible criterion, and to determine whether it is possible to identify predictive factors for HPD.
Mots clés
Chemically induced, Drug therapy, Immune checkpoint inhibitors, Immunotherapy, Melanoma, Nivolumab, Skin neoplasms, Therapeutics, Tumour burden
Référence
Eur J Cancer. 2023 08 11;193:113289